Daniel George, M.D.
Duke Cancer Institute
High-Risk/High-Gain Drug Development: Focusing on Novel Targets to Transform the Field of Prostate Cancer

Samuel Denmeade, M.D.
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Development of a PSMA-Activated Prodrug as Therapy for Metastatic Prostate Cancer

Scott Tagawa, M.D.
Weill Cornell Medical College
Anti-Prostate Specific Membrane Antigen-based Radioimmunotherapy for Castrate Resistant Prostate Cancer

Shaomeng Wang, Ph.D.
University of Michigan
Design of New Cancer Therapies by Targeting Key Apoptosis Regulators and Protein-Protein Interactions